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Abstract
Background: Burning Mouth Syndrome (BMS) is a chronic pain condition characterized by persistent intraoral
burning without related objective findings and unknown etiology that affects elderly females mostly. There is no
satisfactory treatment for BMS. We aimed to observe the long-term efficacy of high velanfaxine doses combined
with systemic and topical administered clonazepam in a particular subgroup of BMS patients who do not respond
to current clinical management.
Results: Eight (66.1 ± 6.2 years old females) out of 14 BMS patients fulfilled the inclusion criteria and were treated
with venlafaxine (300 mg/d) and clonazepam (5 mg/d) for 35.4 ± 12.1 (mean ± SD) months. The average duration
of the symptoms at baseline was 4.3 ± 1.4 years and the overall mean daily pain intensity score was 8.6 ± 1.3 (VAS);
pain was in tongue and within the oral mucosa, accompanying by oral and facial dysesthesia. In five patients
tasting was abnormal. All patients had positive history of concomitant primary headache. The average score of
Hamilton Rating scale for Anxiety and Depression was 21 ± 4.2, and 26.1 ± 2.9, respectively. Previous ineffective
treatments include anticonvulsants and anti-depressants. All patients responded (more than 50% decrease in VAS)
after three months treatment (mean VAS 3.2 ± 2.2) with no remarkable adverse events.
Conclusion: BMS deserves bottomless psychiatric evaluation and management when current available treatments
fail. Treatment with venlafaxine combined with topical and systemic clonazepam may be effective in refractory BMS
cases but further investigation in a large-scale controlled study is needed to confirm these results.
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Background
BMS is a chronic pain condition characterized by
persistent intraoral burning without related objective
findings and unknown etiology that predominantly
affects elderly females. Previously used terms include
stomatodynia, or glossodynia when confined to the
tongue (based on the Greek words stoma that means
mouth and glossa that means tongue). The condition has
been recently recognized in the current International
Classification for Headache Disorders (ICHD-III beta) as
an intraoral burning or dysaesthetic sensation, recurring
daily for more than 2 h per day over more than 3 months,
without clinically evident causative lesions. Oral mucosa
should appear normal with normal sensory testing [1].
How prevalent the condition is remains debatable but
recent general population based studies showed an
incidence of 11.4 per 100,000 person-years [2] and a point
prevalence of 0.11%, or 105.6 (95% CI, 88.6–122.6)
per 100,000 persons [3]. Age-adjusted prevalence in
women was significantly higher than men: 168.6 (95%
CI, 139.0–198.2) vs. 35.9 (95% CI, 21.4–50.3) per
100,000 persons (P < 0.001). The highest prevalence
was in women aged 70 through 79 years (527.9 per
100,000 persons). Mean (SD) age at BMS diagnosis
was 59.4 (15.1) years (range, 25–90 years) [3]. In
other reports the BMS prevalence varies from 3.7%
up to 40% in elderly [4]. Little is known regarding
the aetiopathology of the condition. There is evidence
that BMS is related to mild sensory and autonomic
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small fiber neuropathy with concomitant central
disorders particular within the brainstem [5, 6], as
well as to impaired endogenous dopamine system in
the putamen [7]. In other reports MBS is often co-
morbid with mood and somatoform disorders with
prolong immunoendocrine changes [8]. In some re-
fractory BMS cases comorbided mood disorders are
severe [9, 10]. Altered structure and function in the hippo-
campus and medial prefrontal cortex in BMS patients
explain the concomitant affective conditions [11].
There is no satisfactory treatment for BMS. The most
widely accepted treatment options that show variable re-
sults include tricyclic anti-depressants, benzodiazepines,
antipsychotic drugs [12], and SSRIs [13]. Because there
is enough evidence that in BMS patients TRPV1 recep-
tors are over-expressed [14] local application of capsa-
icin was used efficiently [15]. The best evidence for BMS
treatment includes only topical capsaicin, alpha-lipoic
acid (ALA), and clonazepam [16, 17]. Interestingly, there
are reports of BMS comorbidity with Parkinson disease
(PD) or Restless Syndrome [18–20] and dopamine ago-
nists showed potential efficacy in reducing BMS symp-
toms [21, 22]. Non-pharmaceutical treatments may help
in addition, like cognitive psychotherapy [23]. Neverthe-
less, outcome for BMS is poor. In a study of 91 BMS pa-
tients the symptoms remitted spontaneously within the
five years of treatment. Only 42% of the study popula-
tion had improved the symptomatology significantly,
and this improvement would reach 60% if clonazepam
were associated to psychotherapy [24].
In this study we aimed to observe the long-term efficacy
of high velanfaxine doses combined with clonazepam in a
particular subgroup of BMS patients who do not respond
to current clinical management.
Methods
Patients with burning mouth symptoms that were resistant
to current available treatments were selected at presenta-
tions for long follow-up, since the beginning of 2010. After
the publication of ICHD-III beta all patients fulfilled
the BMS criteria were identified and among them
those they had no improvement after at least three
consecutive drug treatments were followed. Pharma-
cotherapy might include any agent for chronic pain
alone, or in combination with psychotherapy, counting
anti-depressants and anti-epileptics in various doses and
treatment durations, without any specific pattern. After
three consecutive treatment attempts without a 50% re-
duction in daily pain, as defined by patients them selves,
the selection criterion was fulfilled. No exclusion criteria
were applied. Once a patient had recruited, a daily pain
diary was delivered to follow pain duration and severity
during follow-up period. A relevant physician treated
any concomitant non-neurological condition according
to current clinical practice but treatments with local
anesthetics, anti-epileptics and anti-depressants were
not allowed. Antiarrhythmic agents that may have
analgesic effects could be used only after approval by
the research team. All participants were told that they
will get two treatments simultaneously that have been
trialed alone, but not in combination before. The
potential treatment adverse effects were announced as
well. A specific investigation protocol was designed
for diagnostic reasons including brain and facial MRI,
trigeminal blink reflex and peripheral nerve conduc-
tion studies apart from other tests necessary because
of patients’ particular comorbidity and medical history.
Participants allowed to performed neurophysiological
studies of facial nerve in private laboratories, thus no
common methodology used. All patients had a specific
oral and orofacial clinical examination to exclude any oral
condition or temporomandibular joint and occlusion
dysfunction from an expert. In addition all patients had a
neuropsychological evaluation with a battery of tests
including the Hamilton Rating Scales for Anxiety and
Depression, as well as clinical psychiatric consultation. In
all participants cognitive psychotherapy treatment was sug-
gested, in addition to pharmacotherapy. Participants used
the analogue visual scale (VAS) to assess mean daily pain.
In all patients venlafaxine was added at high doses
(300 mg daily), together with clonazepam. Oral solution
of clonazepam was used (Rivortil® oral solution 2.5 mg/
ml). Patients were asked to keep the solution in their
mouth for 5 min before swallowing, in one evening dose
of 2.5 mg. After 5 days the dose increased up to 5 mg
daily, divided into three doses (1.25 mg in the morning,
1.25 in the afternoon and 2.5 mg at bedtime). Always
the solution should be kept in the mouth for at least five
minutes before ingestion. Previous treatments were
removed gradually within 6 months in six cases.
All participants singed inform consent. The Ethical
and Scientific Committee of the Athens Naval Hospital
approved the study.
Results
Eight females out of 14 patients with refractory BMS
cases were included in the protocol. All were above
58 years old (mean ± SD: 66.1 ± 6.2) with the mean
duration of the condition lasting 4.3 ± 1.4 years. All were
followed-up in our department for more than 2 years
(mean follow-up duration 35.4 ± 12.1 months).
Clinical picture and comorbidity
The clinical characteristics of patients are presented
in Table 1. Typically, pain was severe (mean VAS
score 8.6 ± 1.3) and neuralgiform (resembling neuralgia)
in all cases but strictly unilateral only in three cases, lo-
cated within the tongue and the additional oral mucosa.
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In all cases pain was triggered or exaggerated by several
stimuli including mastication, tongue movements, altered
food temperature and six patients had lost wait signifi-
cantly. Pain was daily, lasting for more than two hours
and was typically exaggerated during the bedtime. Accom-
panying local symptoms included mouth dryness, altered
taste and oral dysesthesia. No facial autonomic symptoms
patients reported. All reported previous headaches
classified retrospectively by the authors according to the
ICHD-IIIbeta [1] as migraine in six cases and tension-type
headache in two cases. But during examination and
follow-up none reported concomitant headaches, apart
from unspecified lightheadedness. The most common
general symptoms were fatigue and insomnia, present in
all cases. According to Hamilton rating scale for Depres-
sion (HAM-D) all showed several depressive symptoms
(mean HAM-D26.1 ± 2.9 and for anxiety 21.0 ± 4.2) and all
underwent a psychiatric consultation that revealed depres-
sion, or dysthymia. In five cases depression was already
mentioned in their medical records and has been treated
with several anti-depressants previously. In addition some
cases were also diagnosed with general anxiety disorder, or
somatoform disorder, or panic attacks by psychiatrists. The
most common additional concomitant medical condition
was arterial hypertension, followed by Parkinson disease
(PD) and hypothyroidism (Table 1). No patient needed
antiarrhythmic agents. Notably, only three patients had the
BMS diagnosis previously. Three patients had no diagnosis
and two had the diagnosis of atypical orofacial pain.
Neurological and physical examination were normal in
all cases apart from those they co-suffered from PD
(only mild extrapyramidal symptoms and sings; all three
cases were l-dopa responders to mild doses). Sensory
tests in face for small and large fibers were within
normal limits in all patients (no distal loss of pinprick or
thermal sensation, nor punctate hyperalgesia or brush
evoked allodynia were observed). Bilateral tongue taste
tests (using salty, bitter, sour or sweet solutions) were
abnormal however in five cases (patients also reported
changes in taste). Testing was unpleasant in all cases
because it triggered pain.
Paraclinical investigation
Brain and facial MRI was performed in all cases. In five
patients medium small vessel disease was found in brain
with periventricular location. In one patient lacunes with
midbrain were seen in addition. Facial MRIs showed no
abnormalities related to BMS clinical picture. Facial
Table 1 Clinical characteristics of patients
Case 1 2 3 4 5 6 7 8 Mean (±SD)
Age at presentation 60 58 62 68 71 73 63 74 66.1 (6.2)
Mean pain severity (0–10) 7 8 7 9 8 6 7 9 7.6 (1.2)
Disease duration since first
symptom (years)
3.5 2 3 5 4 5.5 6.5 5 4.3 (1.4)
Pain location in tongue Bil. Un. Bil. Un. Bil. Bil. Un. Bil.
Pain location in additional oral
mucosa
Yes Yes No Yes Yes Yes No Yes
Pain duration per day in hours >8 >6 >6 3–8 2–4 4–8 >6 >10 >2
Pain during night Yes Yes Yes Yes Yes Yes Yes Yes
Mouth dryness Yes No Yes No Yes Yes No Yes
Altered taste Yes No Yes No Yes Yes No Yes
Oral dysaesthesia Yes Yes Yes Yes Yes Yes Yes Yes
Facial dysaesthesia No No No Yes No No No Yes
Follow-up (months) 27 16 37 48 52 34 26 43 35.4 (12.1)
Number of previous
treatments
3 4 5 4 6 4 8 5 4.9 (1.5)
Comorbidity HY, HT OB, HY DP, OB HY, PD, DP HT, DP CH, CHD HT, DP, PD DP, HY
History or concomitant
primary headache
Yes Yes Yes Yes Yes Yes Yes Yes
HAM-A 17 16 20 17 24 28 24 22 21 (4.2)
HAM-D 21 24 25 25 30 29 28 27 26.1 (2.9)
Taste tests Abnormal/Bi Normal Abnormal/Bi Normal Abnormal/Bi Abnormal/Bi Normal Abnormal/Bi
Bil. Bilateral, Un. Unilateral, HY Hypertension, HT Hypothyroidism, OB Obesity, DP Depression, PD Parkinson Disease, CHD Coronary Heart Disease, HAM-A Hamilton
rating scale for anxiety, HAM-D Hamilton rating scale for Depression. Number of previous treatments refers to drugs the patients had given for Burning Mouth
Syndrome specifically and not for any other comorbid condition
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nerve conduction studies were normal in all cases
(velocity was within the normal values adjusted for
patients’ age). In three cases ipsilateral to pain a slight
decrease in facial nerve conduction was observed (still
within the normal values) and blink reflexes were per-
formed that were normal (R1 and R2 responses) without
significant differences between two sites (patient with
midbrain lacunas included). Thus, in all cases paraclinical
investigation, including routine blood tests (CRP, leuco-
cytes) did not reveal any significant abnormality, related to
patients’ symptoms.
Treatment and outcome
Previous treatments included anticonvulsants (pregaba-
line, gabapentine, topiramate, carbamazepine, lamotrigine
and phenyntoin) and anti-depressants (amitriptyline, ven-
lafaxine, mirtazapine and duloxetine) in various doses
(Table 2). No patient received treatment with a topical
anesthetic during the observation treatment period.
In cases 3 and 8 (Table 2) gabapentin 600 mg/day and
carbamazepine 400 mg/day were continued because pain
relapsed after withdrawal. Only three patients accepted
to perform psychotherapy (cases 2, 3 and 7). All eight
patients responded (more than 50% decrease in pain in-
tensity daily) after three months treatment (mean VAS
2.8 ± 2.2). Three out of eight patients became pain free
and two reported more than 75% decrease of pain severity,
but within the entire period of follow-up, almost all
patients relapsed. Relapses were treated successfully by
adding 1.25–2.5 mg/day of clonazepam. For one pain-
free-patient who was not relapsed treatment was discon-
tinued after one year; she regressed and treatment
restarted over again (Fig. 1). Treatment adverse events in-
cluded sedation (in 5 out of 8 patients), dry mouth (8/8),
constipation (6/8), increase in blood pressure (1/8), drow-
siness (8/8), fatigue (3/8) and irritability (1/8). By time
these adverse events were tolerated remarkably. Two cases
were overused clonazepam (up to 10 mg per day) and
managed appropriately. All patients stated they were satis-
fied by the treatment offered but they dislike taking drugs
continuously to treat their condition.
Discussion
BMS is rather a rare chronic idiopathic pain condition
affecting 1‰ of people, predominantly elderly women
that often resist to common treatment with anti-
epileptics and anti-depressants. We describe here eight
cases of female patients with refractory BMS and depres-
sion who followed for more than two years. Pain was se-
vere, daily and exaggerated during the night in all cases.
Repetitive trials with anti-depressants and anti-epileptics
agents commonly used in chronic pain syndromes had
failed, but all responded to a combination of high dose
venlafaxine and oral solution of clonazepam. Participants
experienced several adverse events in the treatment initi-
ation but after a while they tolerated it. BMS treatment
remains controversial [25] yet there is little evidence that
topical clonazepam helps [16]. Indeed all patients re-
ported immediate pain improvement after clonazepam
oral solution. Furthermore, increased clonazepam dose
was used to treat all relapses observed successfully. As
in previous reports clonazepam was used in combination
of oral topical and systematic administration [26]. We
used clonazepam mouthwash as reported by others [27].
Clonazepam’s mechanism of action in BMS stays
unspecified. The drug binds to the peripheral GABAA
receptors that have been identified within the tongue
nerve fibers of rats [28] and enhances GABA inhibitory
effects that may control pain pathways. Additionally, clo-
nazepam promotes brain stem serotonergic descending
pain inhibition by binding to the central GABAA recep-
tors located within the brainstem [29]. Because of this
dual-site action of clonazepam (peripheral and central)
the drug was given both systematically and locally in our
patients. Clonazepam is a long acting benzodiazepine
agonist with low risk of abuse, often used for in short-
acting benzodiazepine withdrawal. However, there are
observations suggesting the existence of its abuse [30].
No case of clonazepam abuse was observed in our study.
Venlafaxine, a serotonin-norepinephrine reuptake inhi
bitor (NSRI) that controls equally depression and
chronic pain [31, 32] was selected to combine clonaze-
pam. Venlafaxine inhibits serotonin and norepinephrine
reuptake leading to enhanced descending inhibition of
Table 2 Previous treatments that failed to improve BMS
Case 1 Pregabaline 150 mg/d plus topiramate 200 mg/d for 5 months; carbamazepine 800 mg/d for 3 months
Case 2 Pregabaline 75 mg/d for 3 months; amitriptyline 75 mg/d for 6 months; phenyntoin 300 mg/d for 2 months
Case 3 Gabapentine up to 2.400 mg/d for 3 months; amitriptyline 75 mg/d plus carbamazepine 400 mg/d for 3 months
Case 4 Amitriptyline 100 mg/d for 6 months; gabapentine 1.800 mg/d plus duloxetine 60 mg/d for 3 months
Case 5 Pregabaline 300 mg/d plus duloxetine 60 mg/d for 3 months; carbamazepine 600 mg/d for 3 months
Case 6 Venlafaxine 150 mg/d plus gabapentine 1.600 mg/d for 3 months; amitriptyline 75 mg/d plus topiramate 200 mg/d for 3 months
Case 7 Pregabaline 150 m/d plus amitriptyline 75 mg/d for 1 month; carbamazepine 800 mg/d for 1 month
Case 8 Carbamazepine 800 mg/d plus mirtazapine 30 mg/d for 3 months; douloxetine 90 mg/d plus lamotrigine 200 mg/d for 3 months
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centrally sensitized pain and has been used to treat pain
conditions comorbid with depression [33]. Whether BMS,
a chronic pain condition, leads to mood disturbances or in
the contrary, established mental conditions might predis-
pose an individual to symptoms related with BMS remains
unanswered. Repeated observations confirm however that
chronic exposure to either pain or stress can guide to
maladaptive hormonal and neuronal modulations that can
result in chronic pain and a wide spectrum of stress-
related disorders including anxiety and depression [34], by
affecting neuropeptide neurotransmission and signaling
within several brain structures including the mesolimbic
dopamine system [35].
Other studies showed that the majority of BMS patients
present with several additional unexplained extra-oral co-
morbidities, indicating that various medical disciplines
should be involved in the BMS diagnostic process and that
BMS may be classified as a complex somatoform disorder
rather than a neuropathic pain entity [36].
This study carries several limitations. It is an uncon-
trolled observational study with a small number of
patients, thus placebo biases cannot be excluded. In a
meta-analysis of placebo-controlled trials for BMS, treat-
ment with placebos produced a response that was 72% as
large as the response to active drugs [37]. These high pla-
cebo response rates documented in this review pose a sig-
nificant challenge for the design of future controlled
studies evaluating therapies for BMS. The aim of our study
however, was to explore the potential efficacy of a combin-
ation of two pharmaceutical agents in a very selective
group of BMS patients. Future controlled large scale stud-
ies are needed to provide good evidence of the suggested
treatment benefits. Some patients included in this study
may have not the typical clinical characteristics of BMS,
e.g. pain during the night and unilateral burning, but this
was the patients’ clinical picture we observed. Patients did
not undergo an intraoral quantitative sensory test that has
been shown to be abnormal in recent reports indicating
significant loss of thermal function but not mechanical
function in BMS patients, supporting the hypothesis that
BMS may be a probable neuropathic pain condition [38].
BMS is often misdiagnosed and pain physicians or
headache specialists should be aware of the condition.
Notably, brain and facial MRI and facial nerve conduc-
tion studies showed no significant findings. Secondary
burning sensation due to drugs (e.g. angiotensin convert-
ing enzyme inhibitors, dopaminergic agonists) or thyroid
hormone dysregulation should be ruled. BMS has high
psychiatric comorbidity but can occur in the absence of
psychiatric diagnosis. Patients with atypical chronic pain
syndromes must be considered as potential candidates
for under-diagnosed depression (major) and suicidal
thoughts. Other common BMS comorbidities include PD
that should be treated accordantly. Thus, BMS manage-
ment requires multidisciplinary management.
Conclusions
Refractory BMS deserves bottomless psychiatric evalu-
ation and management when current available treatments
fail. Paraclinical investigation including brain imaging and
peripheral facial nerve conduction evaluation may be
needed. Controlled, large-scale trials with high dose NSRIs
in combination with mouthwash and systemic clonaze-
pam are required to establish this treatment that might
help to improve pain control in this rare and severely
disable pain condition.
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